← Leaderboards
Kristen Jennifer Brennand
Yale University
$23,065,666
Attributed
$51,941,325
Total exposure
18
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.5M · FY2013–25$10M$7.5M$5M$2.5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$51,941,325 · 18
By mechanism
R01$39,171,054 · 11
RM1$4,152,990 · 1
U01$3,502,080 · 1
RF1$2,360,820 · 1
R56$2,275,377 · 2
R21$459,004 · 1
Top collaborators
- Schahram Akbarian15 shared
- Gang Fang12 shared
- Panagiotis Roussos12 shared
- Paul A Slesinger7 shared
- Joseph D. Buxbaum6 shared
- Vahram Haroutunian6 shared
- Dongming Cai5 shared
- Laura Marianne Huckins5 shared
Most similar at Yale University
Same institution · by research overlap
- Matthew W State$28,201,965
- Donald Eugene Redmond$10,163,975
- Laura Marianne Huckins$7,318,615
- Arvind Krishnamurthy$6,267,701
- Martin A. Schwartz$34,384,106
Others in their field
Top investigators on “Neurons”
- Hongkui Zeng · Allen Institute$106,358,289
- Eric Martin McDade · Washington University$94,632,845
- Ed Lein · Allen Institute$90,858,363
- Randall J Bateman · Washington University$65,841,935
- John Morris · Washington University$65,018,684
- Paul S. Aisen · Cognition Therapeutics, Inc.$58,570,460
Research focus
NeuronsGenesGeneticPhenotypeBrainCell TypeInduced Pluripotent Stem CellSchizophreniaAffectData SetMental DisordersPathway InteractionsAutopsyComplexBaseGenomicsSamplingGene ExpressionTissuesInsightMapsCellsNeurogliaTranscriptomics
Grant awards (70)
High-throughput in vivo and in vitro functional and multi-omics screens of neuropsychiatric and neurodevelopmental disorder risk genes$1,537,668
RM1 · FY2025 · MH
Modeling the interaction of physiological and environmental stressors on common variants to psychiatric traits$993,652
R01 · FY2025 · ES
Functional convergence following disruption of diverse genes associated with neurodevelopmental disorders$846,631
R01 · FY2025 · MH · contact PI
Resolving complex alternative splicing of psychiatric disease genes using single-cell approaches$842,455
R01 · FY2025 · MH
Modeling the impact of regulatory and splicing variants on cellular function in Alzheimer's disease$772,791
R01 · FY2025 · AG
Team science approach to integrate machine-learning models and functional genomics to study aging in the context of Alzheimer's disease$219,882
R21 · FY2025 · AG · contact PI
High-throughput in vivo and in vitro functional and multi-omics screens of neuropsychiatric and neurodevelopmental disorder risk genes$1,488,732
RM1 · FY2024 · MH
Modeling the interaction of physiological and environmental stressors on common variants to psychiatric traits$959,532
R01 · FY2024 · ES
Functional convergence following disruption of diverse genes associated with neurodevelopmental disorders$845,729
R01 · FY2024 · MH · contact PI
Novel Network Biology Approaches to Reposition FDA-approved Drugs for Alzheimer's Disease$844,721
R01 · FY2024 · AG
Resolving complex alternative splicing of psychiatric disease genes using single-cell approaches$841,691
R01 · FY2024 · MH
Modeling the impact of regulatory and splicing variants on cellular function in Alzheimer's disease$838,586
R01 · FY2024 · AG
Team science approach to integrate machine-learning models and functional genomics to study aging in the context of Alzheimer's disease$239,122
R21 · FY2024 · AG · contact PI
High-throughput in vivo and in vitro functional and multi-omics screens of neuropsychiatric and neurodevelopmental disorder risk genes$1,126,590
RM1 · FY2023 · MH
Modeling the interaction of physiological and environmental stressors on common variants to psychiatric traits$931,096
R01 · FY2023 · ES
Novel Network Biology Approaches to Reposition FDA-approved Drugs for Alzheimer's Disease$846,972
R01 · FY2023 · AG
Higher Order Chromatin and Genetic Risk for Schizophrenia$815,593
R01 · FY2023 · MH
Functional convergence following disruption of diverse genes associated with neurodevelopmental disorders$757,807
R01 · FY2023 · MH · contact PI
Resolving complex alternative splicing of psychiatric disease genes using single-cell approaches$756,883
R01 · FY2023 · MH
Cell-type-specific NRXN1alpha alternative splicing changes in psychiatric disease$741,061
R01 · FY2023 · MH
Functional genomic resource and integrative model of dopaminergic circuitry associated with psychiatric disease$660,307
U01 · FY2023 · DA
Shared Genetics and Risk Factors Between Epilepsy and Psychiatric Disease$525,598
R01 · FY2023 · NS · contact PI
2023 Functional Genomics of Human Brain Development and Disease Gordon Research Conference$20,000
R13 · FY2023 · MH · contact PI
Novel Network Biology Approaches to Reposition FDA-approved Drugs for Alzheimer's Disease$847,014
R01 · FY2022 · AG
Higher Order Chromatin and Genetic Risk for Schizophrenia$815,593
R01 · FY2022 · MH
Resolving complex alternative splicing of psychiatric disease genes using single-cell approaches$809,669
R01 · FY2022 · MH
Functional convergence following disruption of diverse genes associated with neurodevelopmental disorders$796,537
R01 · FY2022 · MH · contact PI
Cell-type-specific NRXN1alpha alternative splicing changes in psychiatric disease$783,464
R01 · FY2022 · MH
Modeling the interaction of physiological and environmental stressors on common variants to psychiatric traits$757,349
R01 · FY2022 · ES
Functional genomic resource and integrative model of dopaminergic circuitry associated with psychiatric disease$660,307
U01 · FY2022 · DA
Shared Genetics and Risk Factors Between Epilepsy and Psychiatric Disease$490,771
R01 · FY2022 · NS · contact PI
Modeling the impact of regulatory and splicing variants on cellular function in Alzheimer's disease$2,360,820
RF1 · FY2021 · AG
Functional convergence following disruption of diverse genes associated with neurodevelopmental disorders$873,525
R01 · FY2021 · MH · contact PI
Resolving complex alternative splicing of psychiatric disease genes using single-cell approaches$872,931
R01 · FY2021 · MH
Novel Network Biology Approaches to Reposition FDA-approved Drugs for Alzheimer's Disease$847,487
R01 · FY2021 · AG
Higher Order Chromatin and Genetic Risk for Schizophrenia$815,593
R01 · FY2021 · MH
Cell-type-specific NRXN1alpha alternative splicing changes in psychiatric disease$789,905
R01 · FY2021 · MH
Critical assessment of DNA adenine methylation in brain cells from healthy aging and Alzheimer's disease$745,674
R56 · FY2021 · AG
Functional genomic resource and integrative model of dopaminergic circuitry associated with psychiatric disease$722,242
U01 · FY2021 · DA
Large-scale reprogramming and expression analysis of patient-derived neural cells in schizophrenia$498,247
R01 · FY2021 · MH
Functional genomic resource and integrative model of dopaminergic circuitry associated with psychiatric disease$14,740
U01 · FY2021 · DA
Higher Order Chromatin and Genetic Risk for Schizophrenia$858,519
R01 · FY2020 · MH
Novel Network Biology Approaches to Reposition FDA-approved Drugs for Alzheimer's Disease$845,873
R01 · FY2020 · AG
Cell-type-specific NRXN1alpha alternative splicing changes in psychiatric disease$809,441
R01 · FY2020 · MH · contact PI
Large-scale reprogramming and expression analysis of patient-derived neural cells in schizophrenia$804,759
R01 · FY2020 · MH
Functional genomic resource and integrative model of dopaminergic circuitry associated with psychiatric disease$722,242
U01 · FY2020 · DA
Integrated Multiscale Networks in Schizophrenia$691,233
R01 · FY2020 · MH
Cell-type-specific NRXN1alpha alternative splicing changes in psychiatric disease$422,485
R01 · FY2020 · MH · contact PI
Higher Order Chromatin and Genetic Risk for Schizophrenia$888,002
R01 · FY2019 · MH
Cell-type-specific NRXN1alpha alternative splicing changes in psychiatric disease$812,916
R01 · FY2019 · MH · contact PI
Large-scale reprogramming and expression analysis of patient-derived neural cells in schizophrenia$801,762
R01 · FY2019 · MH
Modeling the contribution of common variants to schizophrenia risk$751,020
R56 · FY2019 · MH · contact PI
Functional genomic resource and integrative model of dopaminergic circuitry associated with psychiatric disease$722,242
U01 · FY2019 · DA
Integrated Multiscale Networks in Schizophrenia$643,698
R01 · FY2019 · MH
Large-scale reprogramming and expression analysis of patient-derived neural cells in schizophrenia$289,041
R01 · FY2019 · MH
Integrated Multiscale Networks in Schizophrenia$35,937
R01 · FY2019 · MH
Large-scale reprogramming and expression analysis of patient-derived neural cells in schizophrenia$799,467
R01 · FY2018 · MH
Modeling the contribution of common variants to schizophrenia risk$778,683
R56 · FY2018 · MH · contact PI
Integrated Multiscale Networks in Schizophrenia$660,426
R01 · FY2018 · MH
Higher Order Chromatin and Genetic Risk for Schizophrenia$643,901
R01 · FY2018 · MH
Large-scale reprogramming and expression analysis of patient-derived neural cells in schizophrenia$853,822
R01 · FY2017 · MH
Higher Order Chromatin and Genetic Risk for Schizophrenia$644,437
R01 · FY2017 · MH
Integrated Multiscale Networks in Schizophrenia$494,832
R01 · FY2017 · MH
Contrasting causal microRNAs in forebrain and midbrain COS hiPSC neural cells$462,667
R01 · FY2017 · MH · contact PI
Contrasting causal microRNAs in forebrain and midbrain COS hiPSC neural cells$677,254
R01 · FY2016 · MH · contact PI
Higher Order Chromatin and Genetic Risk for Schizophrenia$652,734
R01 · FY2016 · MH
Contrasting causal microRNAs in forebrain and midbrain COS hiPSC neural cells$660,304
R01 · FY2015 · MH · contact PI
Higher Order Chromatin and Genetic Risk for Schizophrenia$605,291
R01 · FY2015 · MH
Contrasting causal microRNAs in forebrain and midbrain COS hiPSC neural cells$521,179
R01 · FY2014 · MH · contact PI
Contrasting causal microRNAs in forebrain and midbrain COS hiPSC neural cells$432,191
R01 · FY2013 · MH · contact PI